Pseudopheochromocytoma With Catecholamine Excess and End-organ Damage: A 30-year Course Treated With Escitalopram
Pseudopheochromocytoma is a disorder characterized by paroxysmal hypertension and variably elevated catecholamine metabolite levels. Pseudopheochromocytoma clinically mimics pheochromocytoma but differs in etiology. While pheochromocytoma is a catecholamine-secreting neuroendocrine tumor, pseudopheochromocytoma is a syndrome linked to a history of emotional stressors and is believed to stem from autonomic nervous system dysregulation. We present the case of a 70-year-old female patient experiencing episodic hypertensive crises for 3 decades. The patient was referred to endocrine oncology for evaluation of a possible pheochromocytoma due to her long-standing history of symptomatic hypertension and elevated catecholamine metabolites. Anatomic and functional imaging, including computed tomography scans of the abdomen and pelvis and a <sup>64</sup>Copper-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-octreotate positron emission tomography computed tomography excluded a diagnosis of pheochromocytoma or paraganglioma. Her history of significant emotional stressors raised the possibility of pseudopheochromocytoma. Following initiation of escitalopram and psychotherapy, the patient experienced a remarkable improvement in the frequency and severity of hypertensive episodes. This case illustrates the diagnostic challenges of pseudopheochromocytoma and the importance of early intervention in preventing complications.
Authors
- Leor Needleman (ORCID: https://orcid.org/0009-0006-5637-5591)
- Brian M. Brady (ORCID: https://orcid.org/0000-0003-3882-5270)
- Ayli S Anvaripour
- Justin P Annes
Institutions
- Stanford Medicine (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Stanford University (US)
Publication Details
- Journal
- JCEM Case Reports
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1210/jcemcr/luaf321
- Primary Topic
- Adrenal and Paraganglionic Tumors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases